 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Personalized Medicine in 2012: Industry Takes a Wait-and-See Approach Due to Market Unknowns
January 09, 2013
Personalized Medicine in 2012: Industry Takes a Wait-and-See Approach Due to Market Unknowns
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- With Decode Purchase, Amgen Gains Genetics Expertise, Consumers Lose DTC Testing Option
December 12, 2012 / Pharmacogenomics Reporter - MDx/CDx Focus: EMA Okays Perjeta; Published Study on Prolaris; HER2 Tests for Kadcyla Clear FDA
March 6, 2013 / Pharmacogenomics Reporter - Dx Developers' Sales Pitch to Pharma Could be Key Factor in Marketing Some Tests
February 15, 2012 / Pharmacogenomics Reporter - Personalized Medicine in 2011: Some Successes, Slow Progress, Continued Economic Woes
January 4, 2012 / Pharmacogenomics Reporter - New Firm MetaDiagnostic Moves in to Help Dx Developers, Payors as PBMs Shift from Personalized Rx
August 29, 2012 / Pharmacogenomics Reporter